Cheol-Kyu Park
Overview
Explore the profile of Cheol-Kyu Park including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Jeong S, Kim Y, Noh J, Rho K, Kim H, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 40010769
Background: The increased expression of programmed cell death ligand 1 (PD-L1) on a subset of immune cells in the peripheral blood has been frequently observed in patients with cancer, suggesting...
2.
Park C, Khalil M, Pham N, Wong S, Ly D, Sacher A, et al.
JTO Clin Res Rep
. 2025 Feb;
6(3):100781.
PMID: 39990135
Cancer immunotherapy has brought significant clinical benefits to patients with cancer, including those with lung cancer. Patient-derived tumor xenograft mouse models have become the preferred animal model for translational cancer...
3.
Lee S, Kim Y, Jeong S, Rho K, Noh J, Kim H, et al.
Cancer Commun (Lond)
. 2024 Nov;
45(1):58-62.
PMID: 39568320
No abstract available.
4.
Kang D, Choi C, Park C, Oh I, Kim Y, Yoon S, et al.
Tuberc Respir Dis (Seoul)
. 2024 May;
87(4):483-493.
PMID: 38749491
Background: The use of immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer is increasing. Despite ongoing studies to predict the efficacy of ICIs, its use in clinical practice...
5.
Oh H, Bae S, Oh I, Park C, Jung K, Kim D, et al.
Clin Cancer Res
. 2024 Apr;
30(8):1478-1487.
PMID: 38593249
Purpose: RUNX3 is a tumor suppressor gene, which is inactivated in approximately 70% of lung adenocarcinomas. Nicotinamide, a sirtuin inhibitor, has demonstrated potential in re-activating epigenetically silenced RUNX3 in cancer...
6.
Yoon J, Park W, Kim H, Kang H, Park C, Choi W
J Obes Metab Syndr
. 2024 Jan;
33(1):36-44.
PMID: 38246603
Background: Recent lifestyle changes have increased the prevalence of dyslipidemia in Korea. Young men are known to have a low awareness of dyslipidemia and a lack of motivation to maintain...
7.
Jeon D, Park C, Kim S, Park C, Chang Y, Jung C, et al.
Thorac Cancer
. 2024 Jan;
15(6):448-457.
PMID: 38171544
Background: About 3%-5% of non-small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK-positive NSCLC. This study...
8.
Ji W, Oh I, Park C, Yong Lee S, Choi J, Lee J, et al.
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067272
This study aimed to evaluate treatment outcomes and safety of afatinib in patients with squamous cell carcinoma of the lung (LSCC) who progressed after chemotherapy and immunotherapy. We recruited patients...
9.
Park H, Yoon C, Na Y, Lee J, Oh H, Park H, et al.
Sci Rep
. 2023 Oct;
13(1):18126.
PMID: 37872370
In this study, we aimed to investigate the feasibility of serum Krebs von den Lungen-6 (KL-6) as a potential biomarker for treatment-related ILD (TR-ILD) in lung cancer. We recruited patients...
10.
Oh I, Park C, Min K, Min J, Chung C, Yoon S, et al.
Thorac Cancer
. 2023 Aug;
14(27):2777-2784.
PMID: 37567781
Background: Higher concentrations of particulate matter (PM) have been shown to cause deterioration of the symptoms of respiratory and cardiovascular disease in several regional studies. Here, we aimed to investigate...